

# Siel Olbrecht

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2132540/publications.pdf>

Version: 2024-02-01

9  
papers

587  
citations

1478505

6  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

853  
citing authors

#	ARTICLE	IF	CITATIONS
1	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
2	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
3	Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 14-22.	1.4	14
4	Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer. <i>Npj Genomic Medicine</i> , 2022, 7, 30.	3.8	4
5	High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. <i>Genome Medicine</i> , 2021, 13, 111.	8.2	70
6	A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. <i>Cell Research</i> , 2020, 30, 745-762.	12.0	391
7	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 165-171.	3.7	23
8	Antiangiogenic therapies in ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 18-26.	0.5	1
9	Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. <i>European Journal of Cancer</i> , 2017, 86, 5-14.	2.8	49